Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | FEN1 | P39748 | 6/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 3/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.35 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43657 | 0.88 | KDM4E (0.41) | CA12CA9FEN1ERCC1ERCC4 | |
| SCHEMBL9361606 | 0.73 | — | — | |
| SCHEMBL15159454 | 0.71 | KDM4E (0.42) | KDM4EHTTLMNAKMT2AGAA | |
| SCHEMBL12421478 | 0.69 | KDM4E (0.41) | KDM4EHTTLMNAKMT2AGAA | |
| SCHEMBL10758453 | 0.68 | MAPK1 (0.61) | CA12CA9FEN1KDM4ELMNA | |
| SCHEMBL12310076 | 0.56 | ALDH1A1 (0.36) | CA12CA9KDM4EPOLBGAA | |
| SCHEMBL4586117 | 0.56 | KDM4E (0.38) | CA12CA9FEN1ERCC1ERCC4 | |
| SCHEMBL55119 | 0.56 | SRC (0.42) | CA12CA9KDM4ELMNAMEN1 | |
| SCHEMBL15680200 | 0.56 | SRC (0.48) | KDM4EPOLBGAA | |
| SCHEMBL17789200 | 0.55 | ALDH1A1 (0.44) | KDM4EHTTLMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288649-B2 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-7091342-B2 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | ISHII YASUTAKA | 2006-02-09 | — | — | US | disclosed |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1459804-A1 | CATALYSTS COMPRISING CYCLIC ACYLUREA COMPOUNDS AND PROCESSES FOR PRODUCTION OF ORGANIC COMPOUNDS WITH THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | MOGAT2, HAT1, ACOX1 | CA12 1115/4885CA9 534/4885FEN1 2527/4885 |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | MOGAT2, ACSS2, ACOX1 | CA12 1233/4885CA9 621/4885FEN1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.